看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 74.1x - 81.9x | 78.0x |
| Historical Pb Multiple | 12.4x - 95.3x | 17.9x |
| Fair Value | €123.45 - €136.45 | €129.95 |
| Upside | -21.8% - -13.5% | -17.6% |
| Benchmarks | - | Full Ticker |
| Gilead Sciences, Inc. | - | NasdaqGS:GILD |
| Amgen Inc. | - | NasdaqGS:AMGN |
| Biogen Inc. | - | NasdaqGS:BIIB |
| Arcutis Biotherapeutics, Inc. | - | NasdaqGS:ARQT |
| Vanda Pharmaceuticals Inc. | - | NasdaqGM:VNDA |
| AbbVie Inc. | - | DB:4AB |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| GILD | AMGN | BIIB | ARQT | VNDA | 4AB | |||
| NasdaqGS:GILD | NasdaqGS:AMGN | NasdaqGS:BIIB | NasdaqGS:ARQT | NasdaqGM:VNDA | DB:4AB | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | -38.3% | -12.2% | -22.6% | NM- | NM- | -11.6% | ||
| 3Y CAGR | -57.4% | -11.5% | 1.6% | NM- | NM- | -28.2% | ||
| Latest Twelve Months | -91.5% | -39.1% | 40.6% | 46.6% | -853.3% | -12.1% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 12.3% | 23.7% | 22.6% | -6076.5% | 8.6% | 15.2% | ||
| Prior Fiscal Year | 20.9% | 23.8% | 11.8% | -439.8% | 1.3% | 8.9% | ||
| Latest Fiscal Year | 1.7% | 12.2% | 16.9% | -71.3% | -9.5% | 7.5% | ||
| Latest Twelve Months | 1.7% | 12.2% | 16.9% | -71.3% | -9.5% | 7.5% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | 16.3% | 98.6% | 21.1% | -114.7% | 5.5% | 67.1% | ||
| Prior Fiscal Year | 25.7% | 135.8% | 8.2% | -175.8% | 0.5% | 34.9% | ||
| Latest Twelve Months | 2.3% | 67.6% | 10.4% | -113.8% | -3.5% | 61.9% | ||
| Next Fiscal Year | 45.7% | 124.5% | 12.8% | -73.3% | 9.3% | 277.5% | ||
| Two Fiscal Years Forward | 38.9% | 76.7% | 11.3% | 33.9% | 9.6% | 134.1% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 4.6x | 4.7x | 1.8x | 7.8x | 1.3x | 5.6x | ||
| Price / LTM EPS | 276.3x | 38.6x | 10.7x | -11.0x | -13.5x | 74.8x | ||
| Price / Book | 6.9x | 26.9x | 1.0x | 9.7x | 0.5x | 95.3x | ||
| Price / Fwd Book | 5.4x | 13.3x | 0.9x | 21.4x | 0.4x | 25.5x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | 0.5x | 6.9x | 26.9x | |||||
| Historical P/B Ratio | 12.4x | 17.9x | 95.3x | |||||
| Selected P/B Multiple | 74.1x | 78.0x | 81.9x | |||||
| (x) Book Value | 3,325 | 3,325 | 3,325 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | GILD | AMGN | BIIB | ARQT | VNDA | 4AB | |
| Value of Common Equity | 131,744 | 158,768 | 17,123 | 1,565 | 255 | 315,026 | |
| (/) Shares Outstanding | 1,246.6 | 537.7 | 146.4 | 118.6 | 58.3 | 1,769.0 | |
| Implied Stock Price | 105.68 | 295.30 | 116.98 | 13.19 | 4.37 | 178.08 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.13 | |
| Implied Stock Price (Trading Cur) | 105.68 | 295.30 | 116.98 | 13.19 | 4.37 | 157.80 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.13 | |